Latest news articles

Added 2 months ago Drug news

Surufatinib in advanced neuroendocrine tumors – extra-pancreatic,met the primary endpoint of progression free survival

Hutchison China MediTech announced that the independent Data Monitoring Committee of the Phase III pivotal study of surufatinib in advanced...

Added 7 months ago Drug news

FDA grants accelerated approval for Keytruda to treat Merkel call carcinoma. Merck Inc.

Merck Inc., announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of adult and pediatric patients...

Added 9 months ago Drug news

NETTER-1 data shows improved PFS with Lutathera in neuroendocrine tumours.- Novartis.

Novartis announced presentation of a new analysis of Lutathera (lutetium Lu 177 dotatate) NETTER-1 data examining the impact of Lutathera...

Search all news articles for Malignant neoplasm, unspecified site
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Biosimilars Knowledge Centre

Biosimilars Knowledge Centre

What are biologics and how do they differ from small molecule medicines? Discover more about their development, as well as the manufacturing and regulatory processes in the Biosimilars in Oncology Knowledge Centre.

Load more

Journal articles

Liver transplantation in patients with liver metastases from neuroendocrine tumors: A systematic review.

Background: Liver transplantation to treat neuroendocrine tumors, especially in the setting of diffuse liver involvement not amenable to operative resection remains controversial. We sought to perform a systematic review...

Added 1 year ago

Evaluation of Lanreotide Depot/Autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial.

Objective: To evaluate the efficacy and safety of lanreotide depot/autogel 120mg for the control of carcinoid syndrome (CS) symptoms in...

Added 3 years ago

Search all journal articles for Malignant neoplasm, unspecified site
 

CME

Carcinoma of unknown primary origin: diagnosis and management: putting NICE guidelines into practice

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Malignant neoplasm, unspecified site